Simon Shares Insight on Emerging Immunotherapy Regimens in NSCLC – OncLive
OncLiveSimon Shares Insight on Emerging Immunotherapy Regimens in NSCLCOncLiveIn a trial combining immunotherapy with chemotherapy, the phase III KEYNOTE-189 study—the confirmatory trial for the May 2017 FDA approval of pembrolizumab (Keytruda) with ca… Continue reading
